||CCR3 antagonist 1
||CCR3 antagonist 1 is a potent CCR3 antagonist, used for the research of inflammatory and immunologic diseases.
||AZ084 is a potent, selective, allosteric, and oral active CCR8 antagonist (Ki: 0.9 nM). It has the potential to treat asthma.
||CCR1 antagonist 6
||CCR1 antagonist 6 (compound 16q) is a CCR1 antagonist (IC50: 3 nM).
||CCR1 antagonist 7
||CCR1 antagonist 7 (compound 16r) is a CCR1 antagonist (IC50: 4 nM).
||CCR1 antagonist 9
||CCR1 antagonist 9 is an effective and selective CCR1 antagonist (IC50: 6.8 nM in calcium flux assay).
||CCR2 antagonist 1
||CCR2 antagonist 1 is a high-affinity and long-residence-time antagonist of CCR2 (Ki: 2.4 nM).
||CCR2 antagonist 3
||CCR2 antagonist 3 is a CCR2 antagonist.
||CCR5 antagonist 1
||CCR5 antagonist 1 is a CCR5 antagonist extracted from WO 2004054974 A2. It can inhibit HIV replication.
||Cenicriviroc Mesylate is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2 with anti-inflammatory and antiinfective activity.
||Molibresib besylate is an inhibitor of BET bromodomain (IC50: 32.5-42.5 nM).
||GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist. It has the potential for asthma and eosinophilic bronchitis treatment.
||J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR
||JAK-IN-3 is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.
||ML218 inhibits the burst activity in the subthalamic nucleus (STN) neurons. ML218 is an effective, selective, and orally active inhibitor of T-type Ca2+ channel (Cav3.1, Cav3.2, Ca
||PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy. PF-0463481 is an effective and orally active dual CCR2/CCR5 antagonist. It also h
||RS102895 hydrochloride is a potent antagonist of CCR2(IC50 of 360 nM).
||Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist. With IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.
||AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator and it has an IC50 of 1.2 nM for CCR2 Ca2+ flux [2
||BMS CCR2 22
||BMS CCR2 22 is a potent, specific and high affinity CC-type chemokine receptor 2 (CCR2) antagonist. It has excellent binding affinity (binding IC50 of 5.1 nM) and potent functional
||CCR1 antagonist 8
||CCR1 antagonist 8, a third azaindazole series compound, is a CCR1 antagonist (IC50: 1.8 nM in Ca2+ flux assay).
||CCR2-RA-[R] is a C-C chemokine receptor type 2 (CCR2) allosteric antagonist (IC50: 103 nM).
||CCX140 (CCX140-B) is an antagonist of CCR2.
||CCX354 is a CCR1antagonist. It has anti-inflammatory activity.
||YM022 is a highly effective and selective gastrin/cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase
||BX471 is a potent, selective non-peptide CCR1 antagonist.
||NSC5844 (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic activities.
||Arteether is a new, fast-acting antimalarial drug.
||ZK 756326 is a selective, non-peptide CCR8 chemokine receptor agonist (IC50: 1.8 μM, in human; 2.6 μM, in mouse). Displays no activity at CCR4/5 and CXCR3/4 and shows higher 28-
||INCB8761(PF-4136309) is a specific, effective, and orally bioavailable CCR2 antagonist.
||Vicriviroc maleate(Sch-417690) is a piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus. The IC50 value is 0.91 nM in clinical development
||AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor used for asthma research.
||BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.
||SB 297006 is an antagonist of C-C chemokine receptor 3 (CCR3; IC50 = 39 nM), which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ. It is at least 25
||RS 504393 is a highly selective CCR2 chemokine receptor antagonist (IC50s: 89 nM and > 100 μM for human recombinant CCR2 and CCR1).
||Maraviroc is a C-C Chemokine Receptor Type 5 (CCR5) antagonist, and for MIP-1α(IC50=3.3 nM), MIP-1β (IC50=7.2 nM) and RANTES(IC50=5.2 nM).Maraviroc inhibits HIV-1 entry via CCR5
||Bindarit displays specific inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.
||TAK-779 is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).
||DAPTA(TFA) is an inhibitor of CCR5, shows potent anti-HIV activities.
||3-Hydroxymethylcyclopentanone is a precursor to synthesize methyl epijasmonate. 3-Hydroxymethylcyclopentanone compounds, which are useful as intermediates in the preparation of HIV
||INCB3344 is an effective, specific and orally bioavailable CCR2 antagonist with IC50 values of 9.5 nM (mCCR2) and 5.1 nM (hCCR2) in binding antagonism and 7.8 nM (mCCR2) and in 3.8
||MK-0812 is an effective and specific CCR2 antagonist.
||RS102895 is a potent CCR2 antagonist (IC50: 360 nM) and shows no effect on CCR1.
||Cenicriviroc is an orally active, dual antagonist of CCR2/CCR5. It also inhibits both HIV-1 and HIV-2, and displays potent anti-infective and anti-inflammatory activity.